Piper Sandler downgraded Inspire Medical (INSP) to Neutral from Overweight with a price target of $55, down from $85. The stock in premarket trading is down 22%, or $12.04, to $42.80. Piper is “pleased” with Inspire’s Q1 report but struggles to understand the company’s revised fiscal 2026 outlook, which was reduced significantly. The company’s Q2 outlook is “quite soft” with the updated 2026 guide also implying negative year-over-year growth in both Q3 and Q4, the analyst tells investors in a research note. Piper thinks a multi-quarter turnaround is required between for Inspire to return to growth in fiscal 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $50 from $63 at Baird
- Inspire Medical downgraded at BofA on cloudy path back to growth
- Inspire Medical downgraded to Neutral from Buy at BofA
- Inspire Medical downgraded to Neutral from Overweight at Piper Sandler
- Inspire Medical Cuts 2026 Outlook Amid Reimbursement Headwinds